INDIGO Home University of Illinois at Urbana-Champaign logo uic building uic pavilion uic student center

Hydroxyurea with AKT2 inhibition decreases vaso-occlusive events in sickle cell disease mice.

Show full item record

Bookmark or cite this item: http://hdl.handle.net/10027/20499

Files in this item

File Description Format
PDF Hydorxyurea figures.pdf (2MB) Figures PDF
PDF Hydroxyurea with AKT2.pdf (227KB) Manuscript PDF
Title: Hydroxyurea with AKT2 inhibition decreases vaso-occlusive events in sickle cell disease mice.
Author(s): Barazia, A; Li, J; Kim, K; Shabrani, N; Cho, J
Abstract: Heterotypic cell-cell adhesion and aggregation mediate vaso-occlusive events in patients with sickle cell disease (SCD). Although hydroxyurea (HU), an inducer of fetal hemoglobin, is the main therapy for treatment of SCD, it is unclear whether it has immediate benefits in acute vaso-occlusive events in SCD patients. Using real-time fluorescence intravital microscopy, we demonstrated that short-term coadministration of HU and Akti XII, an AKT2 inhibitor, efficiently reduced neutrophil adhesion and platelet-neutrophil aggregation in venules of Berkeley (SCD) mice challenged with tumor necrosis factor α (TNF-α) or hypoxia/reoxygenation. Importantly, compared with HU or Akti XII treatment alone, short-term treatment with both agents significantly improved survival in those mice. We found that the level of plasma nitric oxide species was elevated by HU but not Akti XII, AKT2 phosphorylation levels in activated neutrophils and platelets were reduced by Akti XII but not HU, and the expression of endothelial E-selectin and intercellular adhesion molecule 1 was decreased by either agent. Our results suggest that short-term coadministration of HU and Akti XII has immediate benefits for acute vaso-occlusive events and survival in SCD mice exceeding those seen for single therapy.
Issue Date: 2015-11-26
Publisher: American Society of Hematology
Citation Info: Barazia, A., Li, J., Kim, K., Shabrani, N. and Cho, J. Hydroxyurea with AKT2 inhibition decreases vaso-occlusive events in sickle cell disease mice. Blood. 2015. 126(22): 2511-2517. DOI: 10.1182/blood-2015-02-626234.
Type: Article
Description: This is a non-final version of an article published in final form in Barazia, A., Li, J., Kim, K., Shabrani, N. and Cho, J. Hydroxyurea with AKT2 inhibition decreases vaso-occlusive events in sickle cell disease mice. Blood. 2015. 126(22): 2511-2517. DOI: 10.1182/blood-2015-02-626234.
URI: http://hdl.handle.net/10027/20499
ISSN: 0006-4971
Sponsor: R01 HL109439/HL/NHLBI NIH HHS/United States
Date Available in INDIGO: 2016-05-04
 

This item appears in the following Collection(s)

Show full item record

Statistics

Country Code Views
China 109
United States of America 88
Russian Federation 22
Germany 4
Italy 2

Browse

My Account

Information

Access Key